Neola Medical AB (publ) (NEOLA) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to today's webcast with Neola Medical, where CEO Hanna Sjöström and CFO Christian Gyllenberg will present the report for the second quarter of 2024. After the presentation, there will be a Q&A, so if you have any questions for the company, you can send them in via the form to the right. And with that said, I hand over the word to you Hanna. Well, thank you so much and a very warm welcome everyone. Today, we will present Neola Medical's Q2 report of 2024 and we're excited to summarize an intense and productive first half year where we reach milestones according to our business strategy. So presenting here today is myself, Hanna Schuster, and I'm the CEO since 2019 and CFO Christian Gyllenberg. First, I will present the company, our market, and the significant events during the quarter. And thereafter, Christian will walk you through the numbers and our financial summary. So Neola Medical is a deep tech company and we have developed the world's first medical device for non-invasive continuous monitoring of the lungs of preterm born babies. It's called Neola Neonatal Lung Analyzer. And with this medical device, we're addressing a growing clinical need since we have an increase in babies born too soon. And they are in need of continuous monitoring of the lungs to survive their severe lung complications. We have already, before a CE mark, sold a research version of Neola to an EU university hospital, generating real-world evidence for us. And we're currently in the FDA process, a de novo process, to achieve an FDA grant to take our medical device to the US. We're a listed company on Nasdaq First North Growth Market in Stockholm, and you find us under the ticker Neola. And today, doctors need to wait up to two hours to receive a chest x-ray result showing...